Core Viewpoint - Guoxin Health (000503.SZ) announced a contract with China Guoxin Holdings to develop a legal compliance intelligent review system for equity investments, valued at RMB 2,840,000 [1] Group 1 - Guoxin Health's wholly-owned subsidiary, Guoxin Health Guarantee Service Co., Ltd., will undertake the project [1] - The contract includes responsibilities for application software design, development, handover, training, and related services [1] - The total contract amount is RMB 2,840,000, including tax [1]

截至发稿，国新健康市值为98亿元。 每经头条（nbdtoutiao）——进博会"爆品"来袭！德国"天价"扳手引围观，阿根廷牛儿为中国"贴膘"，卢 旺达咖啡豆火出圈…… （记者 曾健辉） 每经AI快讯，国新健康（SZ 000503，收盘价：10.03元）11月10日晚间发布公告称，公司第十二届第七 次董事会会议于2025年11月10日以现场结合通讯方式召开。会议审议了《关于与中国国新关联交易的议 案》等文件。 2025年1至6月份，国新健康的营业收入构成为：服务业占比100.0%。 ...

Core Points - Guoxin Health announced the transfer of equity stakes in Guangdong Haihong and Hainan Chemical Fiber through its subsidiaries [2] - The company will transfer 25% and 20% stakes in Guangdong Haihong for a total of RMB 70 million [2] - The transaction has been completed with all payments received and registration changes finalized [2] Summary by Categories Company Actions - Guoxin Health's board and shareholders approved the public transfer of equity stakes in Guangdong Haihong and Hainan Chemical Fiber [2] - The stakes will be transferred through Guoxin Health's subsidiaries, Guoxin Health Guarantee Service Co., Ltd. and Guoxin Yikang Data (Beijing) Co., Ltd. [2] Financial Details - The stakes in Guangdong Haihong are being sold for RMB 38.89 million and RMB 31.11 million respectively [2] - The total transaction amount for the 45% stake in Guangdong Haihong is RMB 70 million [2] Completion Status - As of the announcement date, all transaction payments have been received and the business registration changes have been completed [2]

关于公开挂牌转让广东海虹股权的进展公告 证券简称：国新健康 证券代码：000503 编号：2025-69 国新健康保障服务集团股份有限公司 特此公告。 国新健康保障服务集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 董 事 会 一、交易概述 二零二五年十一月五日 国新健康保障服务集团股份有限公司（以下简称"公司"）于 2023 年 9 月 27 日召开的第十一届董事会第十八次会议和 2023 年 10 月 16 日召开的 2023 年第三 次临时股东大会，审议通过了《关于拟公开挂牌转让海南化纤、广东海虹股权的 议案》。公司将通过公司控股子公司国新健康保障服务有限公司（以下简称"国 新健康有限"）、国新益康数据（北京）有限公司（原名为"益康健康服务有限 公司"，以下简称"国新益康"）分别持有的广东海虹药通电子商务有限公司（以 下简称"广东海虹"）25%、20%股权以公开挂牌方式转让，具体内容详见公司 于 2023 年 9 月 28 日、2023 年 10 月 17 日、2023 年 11 月 3 日和 2024 年 11 月 29 日在《中国证 ...

Core Viewpoint - The company has approved the public transfer of equity stakes in Hainan Chemical Fiber and Guangdong Haihong, completing the transfer of a total of 45% equity in Guangdong Haihong for a total of 70 million yuan [1] Group 1: Equity Transfer Details - The company will transfer 25% and 20% equity stakes in Guangdong Haihong through its subsidiaries, Guoxin Health Limited and Guoxin Yikang [1] - The equity stakes were sold for 38.8889 million yuan and 31.1111 million yuan respectively, with both transactions completed through an agreement with Shanghai Furui [1] - The total transaction amount for the 45% equity stake in Guangdong Haihong is 70 million yuan, and the company has received the payment and completed the industrial and commercial registration changes [1]

Core Viewpoint - Guoxin Health's stock price has shown volatility, with a recent increase despite a year-to-date decline, indicating potential investor interest and market dynamics [1][2]. Group 1: Stock Performance - As of November 5, Guoxin Health's stock price rose by 2.27% to 10.35 CNY per share, with a trading volume of 1.52 billion CNY and a market capitalization of 10.135 billion CNY [1]. - Year-to-date, Guoxin Health's stock has decreased by 5.74%, but it has increased by 4.86% over the last five trading days [2]. Group 2: Financial Performance - For the period from January to September 2025, Guoxin Health reported a revenue of 170 million CNY, a year-on-year decrease of 14.87%, and a net profit attributable to shareholders of -138 million CNY, a significant decline of 347.32% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 47.7195 million CNY since its A-share listing [3]. Group 3: Shareholder Structure - As of September 30, 2025, Guoxin Health had 60,600 shareholders, a decrease of 8.38% from the previous period, with an average of 16,152 circulating shares per shareholder, an increase of 9.14% [2]. - The top ten circulating shareholders include Southern CSI 1000 ETF, which holds 7.1776 million shares, down by 90,600 shares from the previous period [3].

国新健康保障服务集团股份有限公司 关于限制性股票激励计划（第一期）回购注销部分限制性股票完成 暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 本次应回购注销限制性股票激励计划（第一期）已授予但尚未解除限售的限制 性股票数量合计2,077,060股，占回购注销前公司总股本的0.21%，涉及激励对象68 人。截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公司完成 了限制性股票激励计划（第一期）中67名激励对象已授予但尚未解除限售的限制性 股票的回购注销手续，实际注销限制性股票2,060,060股，占回购前公司总股本的 0.21%，实际回购资金总金额为10,432,208.6元。剩余1名激励对象持有的本次应被回 购注销的17,000股限制性股票被司法冻结无法注销，待该部分股票解除冻结后，公 司将及时予以办理回购注销手续。本次注销完成后，公司股份总数由981,312,532股 减少至979,252,472股。 国新健康保障服务集团股份有限公司（以下简称"公司"）于2025年2月20日召 开的第十一届董事会第三十六次会议和第十 ...

Core Points - The stock price of Guo Xin Health increased by 2.17% on October 31, reaching 9.88 CNY per share, with a total market value of 9.695 billion CNY [1] - Year-to-date, Guo Xin Health's stock price has decreased by 10.02%, with a recent 5-day increase of 0.41% and a 20-day decrease of 2.95% [2] - The company reported a revenue of 170 million CNY for the first nine months of 2025, a year-on-year decrease of 14.87%, and a net profit of -138 million CNY, a decrease of 347.32% [2] Financial Performance - Guo Xin Health's main business revenue composition includes: digital medical insurance (52.03%), digital pharmaceuticals (26.17%), digital healthcare (17.70%), health services (4.01%), and property leasing (0.09%) [2] - The company has cumulatively distributed 47.7195 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Guo Xin Health is 60,600, a decrease of 8.38% from the previous period [2] - The top ten circulating shareholders include Southern CSI 1000 ETF, holding 7.1776 million shares, a decrease of 90,600 shares from the previous period [3]

Core Viewpoint - WeDoctor Holdings has submitted an IPO application to the Hong Kong Stock Exchange, aiming to list on the main board, with its business model having evolved significantly since its initial application in 2021, now focusing on cost control in medical insurance as a key revenue driver [1][2]. Business Model - The core business of WeDoctor is health management membership services, which accounted for approximately 78% of its revenue as of mid-2025. The revenue model is based on a profit-sharing arrangement with the health insurance fund, contingent on the number of signed members and the budget set by the insurance bureau [2][5]. - WeDoctor's health management services leverage AI to enhance clinical decision-making and optimize medical processes, aiming to reduce unnecessary medical expenses and improve the surplus rate of health insurance funds [5][7]. Financial Performance - In 2024 and the first half of 2025, WeDoctor reported revenues of 5.496 billion and 3.08 billion RMB, respectively, reflecting year-on-year growth rates of 195% and 69%. The health management membership service has shown strong growth, with a 131% increase in revenue in the first half of 2025 [8][9]. - Despite revenue growth, the profit margins for the core health management service were low, with profit margins of 1.9% and 0.7% for 2024 and the first half of 2025, respectively. The cloud pharmacy business also exhibited low gross margins of 3.8% and 3.3% during the same periods [8][9]. Market Position and Valuation Challenges - WeDoctor's business model shares similarities with U.S. Pharmacy Benefit Managers (PBMs), but operates in a more constrained environment dominated by health insurance funds, limiting revenue elasticity and profitability [10][12]. - The timing of WeDoctor's IPO is critical, as the current market sentiment towards internet healthcare has shifted towards a more rational valuation, making it challenging for the company to achieve the high valuations seen in 2021 [13][14]. - The integration of AI into WeDoctor's services is seen as a potential value driver, but investor skepticism regarding the valuation of AI-driven healthcare companies remains a concern [14].

国新健康保障服务集团股份有限公司 股东会议事规则 （2025 年 10 月修订） 第一章 总 则 第一条 为规范国新健康保障服务集团股份有限公司（以下简称"公司"） 行为，保证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称《公 司法》）《中华人民共和国证券法》《上市公司治理准则》《上市公司章程指引》 《上市公司股东会规则》（以下简称《股东会规则》）、《深圳证券交易所股票 上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》（以下简称《规范运作指引》）和《国新健康保障服务集团股份有限公 司章程》（以下简称《公司章程》）的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、《公司章程》及本规则的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开 1 次， 应当于上 ...